Co-morbidity and mortality among patients with interstitial lung diseases: A population-based study
Ole Hilberg
Department of Medicine, Vejle Hospital, Vejle, Denmark
Search for more papers by this authorElisabeth Bendstrup
Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
Search for more papers by this authorAnders Løkke
Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
Search for more papers by this authorAndreas Fløe
Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
Search for more papers by this authorCorresponding Author
Charlotte Hyldgaard
Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
Correspondence: Charlotte Hyldgaard, Department of Respiratory Medicine, Aarhus University Hospital, Nørrebrogade 45, 8000 Aarhus C, Denmark. Email: [email protected]Search for more papers by this authorOle Hilberg
Department of Medicine, Vejle Hospital, Vejle, Denmark
Search for more papers by this authorElisabeth Bendstrup
Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
Search for more papers by this authorAnders Løkke
Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
Search for more papers by this authorAndreas Fløe
Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
Search for more papers by this authorCorresponding Author
Charlotte Hyldgaard
Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
Correspondence: Charlotte Hyldgaard, Department of Respiratory Medicine, Aarhus University Hospital, Nørrebrogade 45, 8000 Aarhus C, Denmark. Email: [email protected]Search for more papers by this authorABSTRACT
Background and objective
Co-morbidities are frequent among patients with interstitial lung diseases (ILD). The objective of this study was to investigate their impact on mortality.
Methods
We used the Danish National Patient Registry (DNPR) to identify all patients with a first-time diagnosis of ILD between 1998 and 2010. Patients with ILD were matched 1:4 with controls from the background population. The burden of co-morbidity was assessed using the Deyo–Charlson co-morbidity score (DCcs). Mortality risks were assessed using Kaplan–Meier survival curves, and hazard rate ratios (HRR) for death were estimated using Cox proportional hazards regression models.
Results
We identified 10 629 patients with ILD with a corresponding incidence estimate of ILD in Denmark of 17.6 per 100 000 inhabitants (95% CI: 16.5–18.7). Mean age was 72 years and 45.6% of the patients were females. Co-morbidity (DCcs ≥ 1) was present in 30% of the ILD patients and 12% of the controls (P < 0.001). The 5-year survival was 56.0% (95% CI: 54.6–56.6) among ILD patients and 84.0% (95% CI: 83.7–84.4) among controls. HRR for death among patients with ILD was 3.82 for males (95% CI: 3.63–4.02) and 3.85 for females (95% CI: 3.62–4.09) with matched controls as reference. Decreasing survival was seen with increasing DCcs for both groups. The 5-year survival for DCcs = 0 was 61% for ILD and 87% for controls compared with 41% versus 58% for DCcs = 2.
Conclusion
Survival was impaired for patients with ILD for all levels of the DCcs, although increasing burden of co-morbidity tended to close the mortality gap.
Supporting Information
| Filename | Description |
|---|---|
| resp13234-sup-0001-AppendixS1.docWord document, 79 KB |
Table S1. List of ICD-10 diagnostic codes used for the assessment of the Deyo–Charlson co-morbidity score. Diagnostic codes for interstitial lung diseases were excluded. Table S2. Distribution of co-morbidities among interstitial lung disease (ILD) patients and controls before and after the diagnosis of ILD according to ICD-10 disease chapters. Table S3. Other respiratory diagnosis assigned before and after the interstitial lung disease diagnosis. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Hyldgaard C, Hilberg O, Muller A, Bendstrup E. A cohort study of interstitial lung diseases in central Denmark. Respir. Med. 2014; 108: 793–9.
- 2Ley B, Bradford WZ, Vittinghoff E, Weycker D, du Bois RM, Collard HR. Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2016; 194: 711–8.
- 3Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PM, Moodley Y, Reynolds PN, Chapman S, Walters EH, Zappala C et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur. Respir. J. 2017; 49: 1601592.
- 4Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir. Med. 2017; 5: 33–41.
- 5Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur. Respir. J. 2015; 46: 1113–30.
- 6Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir. Med. 2014; 108: 647–53.
- 7Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, Heussel CP, Warth A, Kolb M, Herth FJF. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One 2016; 11: e0151425.
- 8Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am. J. Respir. Crit. Care Med. 2017; 195: 557–82.
- 9Kaesmann L, Janssen S, Schild SE, Rades D. Value of comorbidity scales for predicting survival after radiochemotherapy of small cell lung cancer. Lung 2016; 194: 295–8.
- 10Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987; 40: 373–83.
- 11Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 1992; 45: 613–9.
- 12Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J. Clin. Epidemiol. 2004; 57: 1288–94.
- 13Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin. Epidemiol. 2015; 7: 449–90.
- 14Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur. J. Epidemiol. 2014; 29: 541–9.
- 15ICD-10 Version:2016. [Accessed 7 Apr 2017.] Available from URL: www.who.int/classifications/icd10/browse/2016/en
- 16Moua T, Westerly BD, Dulohery MM, Daniels CE, Ryu JH, Lim KG. Patients with fibrotic interstitial lung disease hospitalized for acute respiratory worsening: a large cohort analysis. Chest 2016; 149: 1205–14.
- 17Collard HR, Tino G, Noble PW, Shreve MA, Michaels M, Carlson B, Schwarz MI. Patient experiences with pulmonary fibrosis. Respir. Med. 2007; 101: 1350–4.
- 18Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, Israel-Biet D, Court-Fortune I, Valeyre D, Cordier JF et al.; Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J. 2005; 26: 586–93.
- 19Collard HR, Ward AJ, Lanes S, Cortney Hayflinger D, Rosenberg DM, Hunsche E. Burden of illness in idiopathic pulmonary fibrosis. J. Med. Econ. 2012; 15: 829–35.
- 20Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU et al.; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188: 733–48.
- 21Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, Dawson J, Sathi N, Ahmad Y, Koduri G et al.; on behalf of the British Rheumatoid Interstitial Lung (BRILL) Network. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics – a large multicentre UK study. Rheumatology (Oxford) 2014; 53: 1676–82.
- 22Antoniou KM, Tomassetti S, Tsitoura E, Vancheri C. Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update. Curr. Opin. Pulm. Med. 2015; 21: 626–33.
- 23Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P, Buccioli M, Piciucchi S, Sverzellati N, Dubini A et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest 2015; 147: 157–64.
- 24Sato T, Watanabe A, Kondo H, Kanzaki M, Okubo K, Yokoi K, Matsumoto K, Marutsuka T, Shinohara H, Teramukai S et al.; Japanese Association for Chest Surgery. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J. Thorac. Cardiovasc. Surg. 2015; 149: 64–9, 70.e1–2.
- 25Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K, Fujii Y, Mitsudomi T, Yoshimura M, Maniwa T et al.; Japanese Association for Chest Surgery. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J. Thorac. Cardiovasc. Surg. 2014; 147: 1604–11.e3.
- 26Kreuter M, Ehlers-Tenenbaum S, Schaaf M, Oltmanns U, Palmowski K, Hoffmann H, Schnabel PA, Heußel CP, Puderbach M, Herth FJ et al. Treatment and outcome of lung cancer in idiopathic interstitial pneumonias. Sarcoidosis Vasc. Diffuse Lung Dis. 2015; 31: 266–74.
- 27Dalleywater W, Powell HA, Hubbard RB, Navaratnam V. Risk factors for cardiovascular disease in people with idiopathic pulmonary fibrosis: a population-based study. Chest 2015; 147: 150–6.
- 28Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir. Med. 2009; 103: 927–31.
- 29Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, Dixey J; Early Rheumatoid Arthritis Study (ERAS) Group. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007; 46: 350–7.
- 30Sparks JA, Chang SC, Liao KP, Lu B, Fine AR, Solomon DH, Costenbader KH, Karlson EW. Rheumatoid arthritis and mortality among women during 36 years of prospective follow-up: results from the nurses’ health study. Arthritis Care Res. (Hoboken) 2016; 68: 753–62.
- 31Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, IB MI, Haentzschel H, Gonzalez-Gay MA, Provan S et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 2010; 69: 325–31.
- 32Kyung SY, Byun KH, Yoon JY, Kim YJ, Lee SP, Park JW, Lee BH, Park JS, Jang AS, Park CS et al. Advanced glycation end-products and receptor for advanced glycation end-products expression in patients with idiopathic pulmonary fibrosis and NSIP. Int. J. Clin. Exp. Pathol. 2013; 7: 221–8.
- 33Hunt WR, Zughaier SM, Guentert DE, Shenep MA, Koval M, McCarty NA, Hansen JM. Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014; 306: L43–9.
- 34Karakatsani A, Papakosta D, Rapti A, Antoniou KM, Dimadi M, Markopoulou A, Latsi P, Polychronopoulos V, Birba G, Ch L et al.; Hellenic Interstitial Lung Diseases Group. Epidemiology of interstitial lung diseases in Greece. Respir. Med. 2009; 103: 1122–9.
- 35Thomeer MJ, Vansteenkiste J, Verbeken EK, Demedts M. Interstitial lung diseases: characteristics at diagnosis and mortality risk assessment. Respir. Med. 2004; 98: 567–73.
- 36Zhang Y, Lu N, Peloquin C, Dubreuil M, Neogi T, Avina-Zubieta JA, Rai SK, Choi HK. Improved survival in rheumatoid arthritis: a general population-based cohort study. Ann. Rheum. Dis. 2017; 76: 408–13.
- 37Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ 2016; 352: h6819.
- 38Holland AE, Fiore JF Jr, Bell EC, Goh N, Westall G, Symons K, Dowman L, Glaspole I. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology 2014; 19: 1215–21.
- 39Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med. Res. Methodol. 2011; 11: 83.
- 40Kaunisto J, Kelloniemi K, Sutinen E, Hodgson U, Piilonen A, Kaarteenaho R, Mäkitaro R, Purokivi M, Lappi-Blanco E, Saarelainen S et al. Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis. BMC Pulm. Med. 2015; 15: 92.
- 41Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE Jr et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 2014; 145: 723–8.
- 42Walsh SL, Wells AU, Desai SR, Poletti V, Piciucchi S, Dubini A, Nunes H, Valeyre D, Brillet PY, Kambouchner M et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir. Med. 2016; 4: 557–65.
